Trial Suggests Imatinib Discontinuation Safe, Some Responses Persist
Evidence continues to mount that discontinuing imatinib treatment for chronic myeloid leukemia (CML) in the chronic phase is safe. A new phase II Dutch and Belgian study showed only about two-thirds of patients relapsed after discontinuing treatment with imatinib and cytarabine, and all patients remained sensitive to imatinib after relapse. (Source: Cancer Network)
Source: Cancer Network - September 16, 2013 Category: Cancer & Oncology Source Type: news

Peripheral T-Cell Lymphoma: Time for a T-Cell–Centric Standard of Care
This is an exciting time in the treatment of PTCL, but with this opportunity comes responsibility. The challenge of how to optimize a plethora of promising new therapies for a small number of patients will drive therapeutic decision making for the foreseeable future. (Source: Cancer Network)
Source: Cancer Network - September 15, 2013 Category: Cancer & Oncology Source Type: news

Peripheral T-Cell Lymphoma: What’s the Role for Transplant?
The number of recently approved agents and those under investigation is promising. However, there are currently no recommendations regarding the optimal timing for use of these agents, a reflection of the lack of data in this area and the need for prospective studies. (Source: Cancer Network)
Source: Cancer Network - September 15, 2013 Category: Cancer & Oncology Source Type: news

Collision Renal Cell Papillary and Medullary Carcinoma in a 66-Year-Old Man
The patient is a 66-year-old male who presented to his primary care physician with a 3-week history of painless gross hematuria. He underwent a renal ultrasound that showed a left kidney mass. (Source: Cancer Network)
Source: Cancer Network - September 15, 2013 Category: Cancer & Oncology Source Type: news

Clinical Applications of The Cancer Genome Atlas Project (TCGA) for Squamous Cell Lung Carcinoma
We summarize here key findings from the comprehensive analysis of squamous cell lung cancer by The Cancer Genome Atlas group and discuss the clinical implications of these findings. (Source: Cancer Network)
Source: Cancer Network - September 15, 2013 Category: Cancer & Oncology Source Type: news

Do Oncogenic Drivers Exist in Squamous Cell Carcinoma of the Lung?
The Cancer Genome Atlas provides us with our first thorough insight into the genetic heterogeneity of squamous cell carcinoma of the lung; whether these findings will translate into personalized squamous cell lung cancer therapy is yet to be determined. (Source: Cancer Network)
Source: Cancer Network - September 15, 2013 Category: Cancer & Oncology Source Type: news

Squamous Cell Lung Cancer: Where Do We Stand and Where Are We Going?
The Cancer Genome Atlas results have led to some encouraging advances in the clinical perspective on squamous cell lung cancer and spurred new initiatives targeting patients with squamous cell lung cancer, giving us hope for future improvements in clinical management and therapeutic outcomes for this subgroup of lung cancer patients. (Source: Cancer Network)
Source: Cancer Network - September 15, 2013 Category: Cancer & Oncology Source Type: news

Short Course of Chemo Effective in Early-Stage HER2 Breast Cancer
Combining four cycles of docetaxel and cyclophosphamide with 1 year of trastuzumab may be a viable treatment option for women with HER2-amplified early-stage breast cancer regardless of their TOP2A status, according to the results of a phase II study. (Source: Cancer Network)
Source: Cancer Network - September 14, 2013 Category: Cancer & Oncology Source Type: news

Variations in Melanoma Treatment May Affect Outcomes in Elderly
Older patients with melanoma were diagnosed with thicker melanomas, and experienced longer time to excision and a higher frequency of insufficient excision margins compared with their younger counterparts in a multicenter study in France. (Source: Cancer Network)
Source: Cancer Network - September 13, 2013 Category: Cancer & Oncology Source Type: news

Dasatinib Shows Promise for Pediatric CML, ALL Patients
A phase I study of dasatinib in children and adolescents with chronic myeloid leukemia (CML) and other malignancies determined dosing for further studies and suggested the drug is well tolerated and effective in these patients. (Source: Cancer Network)
Source: Cancer Network - September 13, 2013 Category: Cancer & Oncology Source Type: news

Pazopanib Noninferior to Sunitinib for Metastatic RCC
A head-to-head comparison of pazopanib and sunitinib for the treatment of metastatic renal cell carcinoma showed that the two drugs resulted in similar progression-free survival, but also indicated that pazopanib may have a favorable safety profile. (Source: Cancer Network)
Source: Cancer Network - September 12, 2013 Category: Cancer & Oncology Source Type: news

Slide Show: Nasal Tumors
This nasal tumor slide show features pathology images of nasal neuroblastoma, rhabdomyosarcoma, melanoma, hemangiopericytoma, and lymphoma at various magnifications. (Source: Cancer Network)
Source: Cancer Network - September 12, 2013 Category: Cancer & Oncology Source Type: news

Perceived Cognitive Decline in Breast Cancer Patients
Two studies presented at the ASCO Breast Cancer Symposium 2013 focused on studying cognitive function in women with early-stage breast cancer, focusing on the relationship between perceived and measurable cognitive decline, and factors that may help to predict cognitive decline. (Source: Cancer Network)
Source: Cancer Network - September 11, 2013 Category: Cancer & Oncology Source Type: news

Post-Treatment Biomarker Changes Improved Breast Cancer Survival
About 40% of women experienced a change in at least one biomarker from primary to residual breast cancer after undergoing neoadjuvant chemotherapy, according to the results of a study presented at the ASCO Breast Cancer Symposium. (Source: Cancer Network)
Source: Cancer Network - September 11, 2013 Category: Cancer & Oncology Source Type: news

“Self-Eating” Cells May Help Prevent Melanoma Progression
A new study in early-stage melanoma patients shows that “self-eating” cells, or autophagy, can keep the cancer in check and may lead to a better prognosis. (Source: Cancer Network)
Source: Cancer Network - September 11, 2013 Category: Cancer & Oncology Source Type: news